Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics-Reference-Cited by-同舟云学术

Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics

Published:2019-11 Issue:50 Volume:37 Page:7394-7395
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Vekemans Johan,Moorthy Vasee,Giersing Brigitta,Friede Martin,Hombach Joachim,Arora Narendra,Modjarrad Kayvon,Smith Peter G.,Karron Ruth,Graham Barney,Kaslow David C.

Funder

Bill & Melinda Gates Foundation

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference5 articles.

1. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study;Shi;Lancet.,2017

2. Advances in RSV vaccine research and development – A global agenda;Higgins;Vaccine,2016

3. http://www.who.int/immunization/research/development/ppc_rsv_vaccines/en/.

4. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine;Kim;Am J Epidemiol,1969

5. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease;Collins;Curr Top Microbiol Immunol,2013

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Vaccines for Chronic Respiratory Patients;Archivos de Bronconeumología;2024-09

2. Factors associated with severe respiratory syncytial virus infection among hospitalized children in Thammasat University Hospital;F1000Research;2024-05-17

3. Factors associated with severe respiratory syncytial virus infection among hospitalized children in Thammasat University Hospital;F1000Research;2024-03-27

4. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7–8, 2022;Vaccine;2023-11

5. The attributable fraction of respiratory syncytial virus among patients of different ages with influenza-like illness and severe acute respiratory illness in a high HIV prevalence setting, South Africa, 2012-2016;International Journal of Infectious Diseases;2023-09